ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer to collaborate with PeptiDream

by Jean-François Tremblay
November 27, 2017 | APPEARED IN VOLUME 95, ISSUE 47

The Japanese drug discovery firm PeptiDream has added Bayer to the list of major drug firms with which it collaborates. Its agreement with Bayer involves identifying macrocyclic and constrained peptides from PeptiDream’s peptide library for use against targets selected by Bayer. Promising compounds will be optimized into therapeutic peptides or small-molecule drugs. PeptiDream will receive an up-front fee as part of the agreement and could receive as much as $1.1 billion in milestone payments. The Japanese firm has similar agreements with drugmakers including Merck & Co., Janssen, and Bristol-Myers Squibb.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment